



CUMBERLAND EMERGING TECHNOLOGIES APPOINTS NEW SENIOR EXECUTIVE

NASHVILLE, Tenn. (January 4, 2017) – **Cumberland Emerging Technologies, Inc. (CET)** today announced the appointment of Joshua Trantum, Ph.D. as *CET's Development Director*. His responsibilities at CET will include sourcing, evaluating, and negotiating for new biopharmaceutical product and technology opportunities. He will also contribute to the management, support, and expansion of CET's university collaborations.

Dr. Trantum started his biomedical career as Senior Engineer at Contour Medical Technology where he helped lead the invention, successful development, and FDA approval of a radio-translucent defibrillation medical device which went on to capture a dominant share of the relevant market. He then joined the Covidien – Kendall Healthcare group, a global medical device manufacturer, as Senior Biomedical Engineer. There he managed a medical device project team and served as project leader for product development and commercialization activities.

Dr. Trantum earned his bachelor's degree in biomedical engineering from Vanderbilt University and received his master's in business administration from Emory University. Later, he earned a master's and a doctorate in biomedical engineering from Vanderbilt. While earning his doctorate, Josh co-invented a novel rapid diagnostic technology for which patents are pending.

After earning his Masters and Ph.D., Dr. Trantum was appointed Manager Engineering Projects at Vanderbilt's Biomedical Engineering department. He led a team of 20 researchers supported by a \$5 million global health diagnostics grant funded by the Gates Foundation. He managed the associated intellectual property in coordination with the technology transfer center and also authored a successful grant application, securing \$500,000 in secondary funding and delivered favorable proof of concept results for a multiplexed point of care instrument.

About Cumberland Emerging Technologies Inc.

Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, LaunchTN, and Gloria Pharmaceuticals. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt University and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment, and infrastructure to early-stage life sciences companies.

###